The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.s

Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

Publications

Ayari M, Mtir M, Mami I, Rais L, Ben Azouz S, Douggui H, Jomni T

Tubulointerstitial Nephritis in ANCA-Associated Vasculitis as a Rare Adverse Effect of Adalimumab: A Case Report.

Current drug safety. 2026;21(1):121-125

Chandra T, Tabanor-Gayle JA, Lakshminarayanan S

Adalimumab-induced Anti-neutrophilic Cytoplasmic Antibody Vasculitis: A Rare Complication of an Increasingly Common Treatment.

Cureus. 2019;11(9):e5598

Martín Varas C, Heras M, Saiz A, Coloma R, Calle L, Callejas R, Molina Á, Rodríguez MA, Fernández-Reyes Luis MJ

Antineutrophil cytoplasmic antibodies associated vasculitis in patient with Crohn's disease treated with adalimumab.

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 2017;37(5):560-561

Fournier A, Nony A, Rifard K

[Antineutrophil cytoplasmic antibody associated vasculitis in a patient treated with adalimumab for a rheumatoid arthritis].

Nephrologie & therapeutique. 2009;5(7):652-7